Munich - Delayed Quote EUR

Mind Medicine Inc (MMQ.MU)

5.47

-0.18

(-3.23%)

At close: April 25 at 9:55:00 PM GMT+2

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

NEW YORK, April 24, 2025--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates.

Business Wire 2 days ago

MNMD
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Key Insights Institutions' substantial holdings in Mind Medicine (MindMed) implies that they have significant influence...

Simply Wall St. 3 days ago

MNMD
MindMed Announces New Employee Inducement Grants

NEW YORK, April 21, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price e

Business Wire 4 days ago

MNMD
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

NEW YORK, April 15, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Emerge study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment of MDD. Emerge will evaluate the efficacy and safety of MM120 ODT 100 µg versus placebo and is expected to

Business Wire 11 days ago

MNMD
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks last month

CMND

ATAI

GHRS
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks last month

CYBN

ATAI

CMND
MindMed Appoints Matt Wiley as Chief Commercial Officer

NEW YORK, March 17, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company’s commercial vision and strategy as it prepares for the potential launch of its first product, MM120

Business Wire last month

MNMD
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from tre

TipRanks last month

ATAI

MNMD

CMND
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

NEW YORK, March 06, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights.

Business Wire last month

MNMD
MindMed to Present at Leerink’s Global Healthcare Conference 2025

NEW YORK, March 04, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Leerink’s Global Healthcare Conference:

Business Wire last month

MNMD
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks last month

QNTM

ENVB

CYBN
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

NEW YORK, February 20, 2025--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates.

Business Wire 2 months ago

MNMD
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investor's Business Daily 2 months ago

MNMD

MRNA

CMPS
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, February 04, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference:

Business Wire 2 months ago

MNMD
Mind Medicine doses first patient in Panorama study

Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder. The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants. Published first on TheFly – the ultimate source for real-time, market-movi

TipRanks 2 months ago

MNMD
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

NEW YORK, January 30, 2025--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD). The Panorama study will evaluate the efficacy and safety o

Business Wire 2 months ago

MNMD
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Ascend Wellness secured $15 million to boost growth Leafly Holdings transitioned to OTC trading after Nasdaq delisting High Tide expanded into Germany with strategic acquisition Key Takeaways; Psychedelic Sector MindMed provided investor update with detailed plans for 2025 and beyond Awakn secured unsecured credit facility to support research and development Below […]

Market Exclusive 3 months ago

LFLY

LFLYW

MNMD
MindMed to Be Added to the Nasdaq Biotechnology Index

NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024.

Business Wire 4 months ago

MNMD
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

NEW YORK, December 16, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT

Business Wire 4 months ago

MNMD
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.

Business Wire 4 months ago

MNMD

Performance Overview

Return	MMQ.MU	S&P 500 (^GSPC)
YTD	-13.83%	-6.06%
1-Year	--	+9.44%
3-Year	-53.25%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mind Medicine Inc (MMQ.MU)

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

MindMed Announces New Employee Inducement Grants

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

MindMed Appoints Matt Wiley as Chief Commercial Officer

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink’s Global Healthcare Conference 2025

Psychedelic: GH Research, Compass Pathways report earnings results

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Mind Medicine doses first patient in Panorama study

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Performance Overview